A Randomized Double-Blind Placebo-Controlled Study to Determine Safety of P128 Applied to Nares of Healthy Volunteers and Safety And Efficacy of Any Patient Including Chronic Kidney Disease Patients Who Are Nasal Carriers of S.Aureus.

Trial Profile

A Randomized Double-Blind Placebo-Controlled Study to Determine Safety of P128 Applied to Nares of Healthy Volunteers and Safety And Efficacy of Any Patient Including Chronic Kidney Disease Patients Who Are Nasal Carriers of S.Aureus.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs P 128-GangaGen (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GangaGen
  • Most Recent Events

    • 04 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2014 Planned End Date changed from 1 May 2014 to 1 Apr 2014 as reported by European Clinical Trials Database record.
    • 14 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top